OFIX:NGS-Orthofix International N.V. (USD)

EQUITY | Medical Devices | Nasdaq Global Select

Last Closing

USD 11.25

Change

-0.03 (-0.27)%

Market Cap

USD 0.68B

Volume

0.31M

Analyst Target

USD 47.75
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Orthofix International NV is a diversified medical device company. The Company is engaged in developing and delivering repair and regenerative solutions to the spine and orthopedic markets.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-30 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
DXCM DexCom Inc

N/A

USD 33.20B
PODD Insulet Corporation

N/A

USD 21.86B
MASI Masimo Corporation

N/A

USD 8.49B
BRKR Bruker Corporation

N/A

USD 5.69B
TMDX TransMedics Group Inc

N/A

USD 4.11B
IRTC iRhythm Technologies Inc

N/A

USD 3.38B
PRCT Procept Biorobotics Corp

N/A

USD 3.17B
LIVN LivaNova PLC

N/A

USD 2.40B
SSII SS Innovations International I..

N/A

USD 2.20B
NVCR Novocure Ltd

N/A

USD 1.94B

ETFs Containing OFIX

VXM:CA First Asset Morningstar I.. 0.61 % 0.70 %

N/A

CAD 0.02B

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -35.57% 37% F 20% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -35.57% 37% F 20% F
Trailing 12 Months  
Capital Gain -18.06% 59% D- 38% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -18.06% 59% D- 37% F
Trailing 5 Years  
Capital Gain -66.99% 52% F 21% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -66.99% 52% F 20% F
Average Annual (5 Year Horizon)  
Capital Gain -14.69% 27% F 20% F
Dividend Return -14.69% 27% F 19% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 29.84% 86% B+ 60% D-
Risk Adjusted Return -49.22% 23% F 16% F
Market Capitalization 0.68B 75% C 62% D

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Devices) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 74.00 7% 4%
Price/Book Ratio 1.05 80% 67%
Price / Cash Flow Ratio 18.40 15% 15%
Price/Free Cash Flow Ratio 34.53 6% 11%
Management Effectiveness  
Return on Equity -27.82% 67% 40%
Return on Invested Capital -12.82% 65% 37%
Return on Assets -5.00% 75% 41%
Debt to Equity Ratio 31.21% 60% 49%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector